leisure time -WSS

leisure time

author：entertainment 2025-09-14 10:08:28 - browse：19

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： New weight loss drugs work. But how can they best be used?

WSS

Be careful with at

A single drug, study failures leave Anavex with nothing but cash

New weight loss drugs work. But how can they best be used?

Idaho college killings prosecutors challenge defense's grand jury claims

Burning questions for the 2024 JPM Healthcare Conference

Maui wildfire now ranks as the fifth

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Peter Hotez and the public health issue of online harassment

3 trends to watch in health tech's hiring outlook for 2024

At least 13 dead in Texas as scorching temps continue

Surge in Apellis stock fueled by confidence in safety of its eye drug

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Surge in Apellis stock fueled by confidence in safety of its eye drug

Virginia high school admissions case could be legal follow

Maui wildfire now ranks as the fifth

What does generative AI mean for health care? We asked experts

Morgan Health, with ambitious aims, wants you to know it’s still here

leisure time

Health AI: on the border between health care and tech

Goldman Sachs launches $650M fund for life science investments

Biogen’s boardroom scandal saddles CEO with first crisis

Antibiotic resistance and the global rise in human conflict

Burning questions for the 2024 JPM Healthcare Conference

Burning questions for the 2024 JPM Healthcare Conference

leisure time

explore

explore

hotspot